Your search for "press releases" return 16 results.
CEVA EXPANDS ORAL RABIES VACCINE PORTFOLIO WITH THE ACQUISITION OF CANADIAN FIRM ARTEMIS TECHNOLOGIES, INC. >
Libourne, May 16, 2022 – Ceva Santé Animale (Ceva) has acquired the Canadian oral rabies vaccine manufacturer Artemis Technologies, Inc. Artemis, located in Guelph, ON, Canada, produces ONRAB®, a ra...
Ceva urges volunteers to follow new AHS “best practices” to help stop heartworm transmission via transported dogs.
2016 was a year of sustained organic growth and major acquisitions. Consolidated sales reached €912m.
Phase 2 Study calls for fighting both the mosquito and the heartworm
Ceva receives contract to produce avian influenza vaccine.
Craig Wallace named finalist for the EY Entrepreneur Of The Year® 2015 Award in the Central Midwest >
EY Entrepreneur Of The Year is the world’s most prestigious business award for entrepreneurs.
Ceva leases 72,000 square feet of warehousing and distribution space in Hunt Midwest SubTropolis
A new Salmonella vaccine will offer poultry producers a unique opportunity to strengthen their existing Salmonella prevention programs.
In connection with a trademark infringement lawsuit brought by PSPC, Inc. against Sogeval Laboratories, Inc. in the United State District Court for the Middle District of Florida, the parties have ent...
French veterinary pharmaceutical companies Ceva Santé Animale (Ceva), based in Libourne, and Sogeval (a subsidiary of Sofiprotéol), based in Laval have entered into exclusive merger negotiations.